Ropes & Gray represented CANbridge Pharmaceuticals, a China-based biopharmaceutical company, in its exclusive worldwide license agreement with UMass Chan Medical School relating to the development and commercialization of a novel second-generation gene therapy for treatment of spinal muscular atrophy. The agreement was announced on January 4.
The CANbridge Pharmaceuticals team was led by IP transactions partner David McIntosh.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.